Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oncolytic herpes simplex virus type 1
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intralesional, Intracerebral
01
Overview
Oncolytic Herpes Simplex Virus Type 1 (oHSV1) is a therapeutic platform consisting of genetically engineered HSV-1 strains designed to selectively replicate in and destroy cancer cells while inducing a systemic antitumor immune response. These viruses are typically modified by deleting neurovirulence genes (such as γ34.5/ICP34.5) to ensure safety and tumor selectivity, and often incorporate immunostimulatory transgenes like GM-CSF to enhance the recruitment and activation of dendritic cells and T-lymphocytes. In the treatment of glioblastoma multiforme (GBM), oHSV1 candidates like teserpaturev have demonstrated clinical efficacy, leading to regulatory approval in Japan. Recent research has identified the non-canonical BAF (ncBAF) complex subunit BRD9 as a pivotal tumor-intrinsic resistance factor; BRD9 promotes the expression of antiviral genes that limit viral replication, and its inhibition has been shown to significantly sensitize GBM models to oHSV1-mediated oncolysis.
- Brand names
- ImlygicDelytact
- Other names
- oHSV1oHSV-1oHSV 1oncolytic HSV-1oncolytic herpes simplex virus type 1
Beyond the preview
Go deeper on oncolytic herpes simplex virus type 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oncolytic herpes simplex virus type 1.